Rhythm Pharmaceuticals (RYTM) Other financing activities (2018 - 2026)

Rhythm Pharmaceuticals (RYTM) has reported Other financing activities for 9 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other financing activities rose 46.49% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $189.1 million (up 5458.78% YoY), while the FY2025 annual figure was $188.7 million, up 2019.74% from the prior year.
• Other financing activities fell to $1.3 million in Q1 2026 per RYTM's latest filing, from $177.5 million in the prior quarter.
• Across five years, Other financing activities topped out at $177.5 million in Q4 2025 and bottomed at -$6.5 million in Q3 2024.
• Historically, Other financing activities has averaged $12.5 million across 5 years, with a median of $1.3 million in 2024.
• Annual changes were most pronounced in 2024 — Other financing activities tumbled 511.22% — and 2025, when it surged 2226.37%.
• Rhythm Pharmaceuticals' Other financing activities stood at -$3.2 million in 2022, then climbed by 23.66% to -$2.5 million in 2023, then soared by 408.78% to $7.6 million in 2024, then soared by 2226.37% to $177.5 million in 2025, then plunged by 99.3% to $1.3 million in 2026.
• Business Quant data shows RYTM's Other financing activities at $1.3 million in Q1 2026, $177.5 million in Q4 2025, and $5.5 million in Q3 2025.